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Abstract
Background: Although blood donations may reduce body iron stores, to date, prospective data on frequent blood donation
and colorectal cancer risk are limited.
Methodology/Principal Findings: We tested whether frequent blood donation is associated with a lower risk of colorectal
cancer in the Health Professionals Follow-up Study. We prospectively followed 35,121 men who provide the information on
lifetime number of blood donations in 1992 through 2008. Serum ferritin levels were measured in a random sample of
305 men. Cox proportional hazard regression models were used to calculate the multivariable relative risks (RRs, 95%CIs)
after adjusting for age and other established colorectal cancer risk factors. We documented 684 incident colorectal cancer
cases and 224 deaths from colorectal cancer. The mean serum ferritin levels varied from 178 mg/L for men who did not
donate blood to 98 mg/L for men who had at least 30 donations. Age-adjusted results for both incidence and mortality were
essentially the same as the multivariable-adjusted results. Comparing with non-donors, the multivariable RRs (95%CIs) for
colorectal cancer incidence were 0.92 (0.77, 1.11) for 1–5 donation, 0.85 (0.64, 1.11) for 6–9 donations, 0.96 (0.73, 1.26) for
10–19 donations, 0.91 (0.63, 1.32) for 20–29 donations, and 0.97 (0.68, 1.38) for at least 30 donations (Ptrend=0.92). The
multivariable RRs for colorectal cancer mortality were 0.99 (0.72, 1.36) for 1–5 donation, 0.93 (0.57, 1.51) for 6–9 donations,
0.85 (0.50, 1.42) for 10–19 donations, and 1.14 (0.72, 1.83) for at least 20 donations (Ptrend=0.82). The results did not vary by
cancer sub-sites, intake levels of total iron, heme iron, or family history of colorectal cancer.
Conclusions/Significance: Frequent blood donations were not associated with colorectal cancer incidence and mortality in
men. Our results do not support an important role of body iron stores in colorectal carcinogenesis.
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Introduction
Iron is an essential mineral but excessive iron has been
hypothesized to influence colorectal carcinogenesis possibly
through forming reactive oxygen species, as shown in vitro studies.
[1,2] In addition, given its abundance in food sources and
widespread use of iron supplementation, the iron and colorectal
cancer hypothesis warrants further investigation. To date,
epidemiological studies of colorectal cancer risk in relation to iron
intakes or markers of body iron stores have yielded conflicting
results. [3,4,5,6,7,8,9,10,11,12,13] The inconsistent findings may
partly be explained by the use of non-specific measures of body
iron stores. [2,9] This limitation could be addressed by using
history of blood donation as a marker of body iron levels. [2] In
men, body iron stores can be halved through the donation of
1 unit per year (U/yr). [14] As shown earlier, [2,15] serum ferritin
level is a reliable measure of body iron stores in healthy individuals
compared to other measures such as serum transferrin and total
iron binding capacity. The hypothesis that the depletion of body
iron stores decreases colorectal cancer risk can be tested by
comparing colorectal cancer risk between frequent blood donors
and non-donors.
To the best of our knowledge, three studies [16,17,18] evaluated
cancer risk among blood donors but the results may mainly reflect
healthy donor effects and none estimated the dose-response
relationship with the number of blood donations. One recent study
in Swedish and Danish blood donors estimated iron loss resulting
from blood donations and found little support for any important
association between blood donation and overall cancer risk (no
separate estimates for colorectal cancer due to the small numbers).
[19] However, factors that do or may influence cancer risk
including smoking, alcohol consumption, diet, body mass index,
and physical activity were not available in that study. [19] The aim
of this study is to examine the association between blood donation
and colorectal cancer incidence and mortality in the Health
Professionals Follow-up Study (HPFS). We hypothesized that
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39319frequent blood donation is associated with a lower risk of
colorectal cancer.
Materials and Methods
Study Population
The HPFS is a prospective cohort study that was initiated in
1986 when 51,529 U.S. male professionals who aged 40 to 75
years were enrolled. [20] Participants have been mailed
questionnaires every 2 years since 1986 to collect data on
demographics, lifestyle factors, medical history, and disease
outcomes. The follow-up rate has been greater than 90%. This
study was approved by the Human Subjects Committee of the
Harvard School of Public Health. As approved by the
committee, return of the questionnaires was considered to imply
informed consent and we also obtained written consent from
each participant to obtain and review medical records. We began
our analysis in 1992 when 46,213 participants returned the
questionnaire in which blood donation history were queried. We
excluded participants who died before 1992 (n=11), or
participants with a history of cancer (n=3,681; except for non-
melanoma skin cancer), or ulcerative colitis (n=398) in 1992. We
further excluded participants with missing data on blood
donation (n=7,002), which left 35,121 men for the analysis.
Men who did not answer the blood donation question did not
differ substantially from respondents according to age, body mass
index, physical activity, endoscopy screening, family history of
colorectal cancer, alcohol consumption, and major dietary factors
(data not shown).
Identification of Incident Colorectal Cancer Cases and
Deaths
Participants reported cancer and other disease outcomes on the
biennial questionnaires. Researchers were given permission by the
study participants to obtain medical records and pathological
reports. Researchers were blinded to exposure information and
reviewed the medical records to abstract information on anatomic
location, stage, and histological type of the cancer. Colon cancer
and rectal cancer were defined according to the International
Classification of Diseases, Ninth Revision (ICD-9). [21] Colon
cancer was further classified into proximal colon cancers
(neoplasms from the cecum to the splenic flexure) and distal colon
cancers (neoplasms in the descending and sigmoid colon). Rectal
cancer was defined as that occurring in the rectosigmoid or
rectum. [21] A total of 684 incident colorectal cancer cases were
documented in this study. Deaths were identified from state vital
statistics records, the National Death Index, reported by the
families, and the postal system. Cause of death was identified from
death certificates or review of medical records. We documented
224 deaths from colorectal cancer in this analysis.
Assessment of Blood Donation and Serum Ferritin
In 1992, the participants were asked to report their blood
donation history (never, 1 to 5, 6 to 9, 10 to 19, 20 to 29, 30 to 59,
60 to 89, and $90 blood donations) during the past 30 years. We
grouped participants with 30 to 59, 60 to 89, and $90 blood
donations into 1 category (i.e., $30) because only relatively few
men donated .30 U of blood. Serum ferritin levels were
measured in a random sample of 123 men in 1986. [22]
Additional samples from another182 men, who provided blood
in 1994, were obtained in a control group of a nested case-control
study of Parkinson disease (Dr. Xiang Gao, personal communi-
cation, 2010). Given similar serum ferritin levels in these two
samples (P-value for test for difference=0.07), we combined them
to examine whether the serum ferritin levels differ by number of
blood donations. CVs for the assays were ,8%.
Assessment of Dietary and Non-dietary Lifestyle Factors
Information on usual dietary intake over the past year was first
assessed using a validated 131-item food frequency questionnaire
(FFQ) in 1986 and every 4 years thereafter. [20] Nine possible
frequency choices were available, ranging from ‘‘almost never’’ to
‘‘6 or more times per day’’. Nutrient intakes were calculated by
multiplying the frequency of each food consumed and the nutrient
content of specified portion sizes. These dietary factors included
total iron, dietary iron, heme iron, iron supplement use; and
information on red meat, processed meat, alcohol, folate, calcium,
vitamin D, fruits, and vegetables was also collected from the
baseline and in subsequent FFQs. In addition, we inquired about
potential colorectal cancer risk factors such as height, body weight,
physical activity (MET-hrs/wk), cigarette smoking, family history
of colorectal cancer, and aspirin use in the biennial questionnaires.
Statistical Analyses
We calculated person-time for each participant from the 1992
questionnaire return to the date of death, colorectal cancer
diagnosis, or the end of follow-up (January 1, 2008), whichever
came first. We used a Cox proportional hazards regression model
[23] to calculate hazards ratios (relative risks or RRs) and 95%
confidence intervals (CIs) and adjusted simultaneously for age (in
months) and year of questionnaire return. In addition to age
adjustment, in the second model, we adjusted for established non-
dietary risk factors, which were queried in 1992 questionnaire. In
the third model, we adjusted for dietary factors (see Table 2
footnote for these variables). We used the 1990 questionnaire for
the dietary factors because no food frequency questionnaire was
administered in 1992. We used median values of blood donation
categories and entered these values as continuous variables to
conduct trend tests. We observed no violation of the proportional
hazard assumption based on the likelihood ratio test that
compared the model with and without the interaction terms
between blood donation and age or follow-up time. Given that
some factors or conditions may potentially influence body iron
stores, [24] we evaluated whether the association with the number
of blood donations varied by age (,65, $65 y), alcohol
consumption (non- to low drinker [,10 g/d], moderate- to
heavy-drinker [$10 g/d]), and total iron and heme iron intakes
(,median, $median). In addition, we conducted sensitivity
analyses restricted to men without gastrointestinal bleeding and
inflammatory conditions such as myocardial infarction, stroke,
coronary artery bypass graft angina or rheumatoid arthritis.
Further, we assessed whether the association was modified by
common colorectal cancer risk factors including endoscopy
screening (no, yes), body mass index (,25, $25 kg/m
2), physical
activity (,30, $30 MET-hrs/wk), and family history of colorectal
cancer (no, yes). The information on these factors was from the
1992 questionnaire.
With regard to ferritin, we conducted regression analyses in
which we regressed the medians of each of blood donation
category (i.e., 0, 3, 7.5, 15, 25, 35) on serum ferritin levels. For
mortality analysis, person-time was calculated from the date of the
baseline questionnaire until the date of death or the end of follow-
up (January 1, 2008), whichever occurred first. We used a Cox
proportional hazards regression model [23] to calculate the RRs
(95% CIs).
All statistical analyses were two-sided with a P-value less than
0.05 indicating significance. We conducted all analyses using the
SAS software (SAS Institute, Inc., Version 9.2, Cary, NC).
Blood Donation and Colorectal Cancer
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A total of 684 incident colorectal cancer cases were documented
during 504,122 person-years of follow-up. As shown in table 1,
although differences in colorectal cancer risk factors between
frequent blood donors and non-donors were quite modest, blood
donation was associated with serum ferritin levels. Among the
305 men, mean ferritin levels across the categories of number of
blood donations were: 178 mg/L for no donations (n=90);
173 mg/L for 1 to 4 donations (n=110); 162 mg/L for 5 to 9
donations (n=36); 129 mg/L for 10 to 19 donations (n=34);
102 mg/L for 20 to 29 donations (n=12); and 98 mg/L for
$30 blood donations (n=23) (Table 1). The regression models
showed that 1 unit change in blood donation (i.e., 1 donation)
results in significant 2.6 mg/L lower levels of serum ferritin
(P=0.002). Results were essentially the same when we further
adjusted for lifestyle and other dietary factors (data not shown).
We found no significant association between the number of
blood donations and incidence of colorectal cancer overall or by
any sub-site (Table 2). The age-adjusted relative risk (RR) was 0.97
(95%CI: 0.68, 1.38, P for trend=0.92) for the highest blood
donation group (i.e., $30) compared with the non-donors. The
RRs were essentially unchanged after adjustment for non-dietary
or dietary factors (Table 2). Further adjustment for iron
supplement use, total iron intake, and heme iron intake (each
factor was added separately to the model) did not change the
observed null associations. In addition, stratified analysis by total
iron intake and heme iron intake (,median, $median) yielded
similar null results (data not shown). Further, as shown in Table 1,
only 2–3% men took iron supplements in 1992, which limited our
ability to restrict our analysis among the iron-supplement user
group (n=28 colorectal cancer cases). The null associations were
not modified by age (,65, $65 y), alcohol consumption (,5 g/d,
$5 g/d), endoscopy screening (no, yes), body mass index (,25,
$25 kg/m
2), physical activity (,30, $30 MET-hrs/wk), and
Table 1. Age-standardized risk factors for colorectal cancer in relation to lifetime number of blood donation in the Health
Professionals Follow-up Study.
No. of blood donations
0 (n=11554) 1–5 (n=11699) 6–9 (n=4082) 10–19 (n=3811) 20–29 (n=1731) $30 (n=1817)
Age, mean (SD), y 61.1(9.9) 59.3(9.5) 58.0(9.1) 57.9(8.8) 57.9(8.8) 58.8(8.4)
Body mass index(kg/m
2), mean (SD)
1 25.4(3.2) 25.6(3.1) 25.7(3.1) 25.9(3.1) 26.1(3.3) 26.0(3.3)
Physical activity (MET-hrs/wk), mean(SD)
2 28.3(28.6) 28.7(27.4) 30.3(28.5) 29.7(26.8) 30.0(27.1) 30.8(28.3)
Family history of colorectal cancer in a parent
or sibling (%)
12 13 13 12 12 13
Former or current smokers (%) 50 51 51 52 50 49
Regular aspirin use (%)
3 43 44 46 46 46 45
Multivitamin use (%) 43 43 43 42 43 42
Ever had a colonoscopy or sigmoidoscopy
before 1992 (%)
44 47 46 48 46 47
Dietary intakes
4, mean (SD)
Total energy intake(kcal/d) 1923(598) 1920(590) 1923(591) 1927(594) 1974(594) 1967(590)
Total carbohydrates (g/d) 249(44) 248(43) 247(41) 245(42) 245(40) 245(39)
Total fat(g/d) 68.5(14.4) 68.7(13.9) 68.9(13.6) 69.7(13.8) 70.1(13.2) 70.3(12.9)
Total protein(g/d) 90.8(16.4) 90.7(15.7) 90.6(15.4) 91.2(15.5) 90.9(15.3) 91.0(15.2)
Fruits and vegetables (servings/d) 5.5(2.6) 5.6(2.6) 5.6(2.4) 5.6(2.6) 5.7(2.5) 5.6(2.5)
Dietary fiber (g/d)
5 22.3(7.7) 22.4(7.3) 22.4(7.2) 22.1(6.9) 22.0(6.9) 22.2(7.2)
Alcohol(g/d) 10.1(14.8) 10.3(14.3) 10.5(14.4) 10.4(13.7) 10.3(13.7) 9.9(13.8)
Total calcium (mg/d)
5 905(409) 904(388) 920(382) 926(390) 914(374) 932(371)
Total vitamin D (IU/d)
5 438(301) 436(295) 432(293) 432(294) 419(276) 427(275)
Total folate (mg/d)
5 507(267) 508(268) 500(259) 500(263) 497(249) 490(240)
Total iron (mg/d)
5 19.6(12.6) 19.5(12.4) 19.2(11.7) 19.2(12.0) 19.3(12.6) 19.8(12.9)
Heme iron (mg/d)
5 1.2(0.5) 1.2(0.5) 1.2(0.5) 1.2(0.5) 1.2(0.4) 1.2(0.4)
I r o n s u p p l e m e n t u s e ( % ) 2323 3 3
Beef, pork, or lamb as a main dish(servings/wk) 1.8(1.5) 1.7(1.4) 1.8(1.4) 1.8(1.4) 1.9(1.4) 1.9(1.6)
Processed meat(servings/wk) 1.1(1.6) 1.1(1.6) 1.1(1.5) 1.2(1.6) 1.2(1.5) 1.3(1.6)
Serum ferritin levels (mg/L)
6,mean (SD) 178 (130.6) 173(124) 162(120) 129(93) 102(56) 98(67)
1Body mass index was calculated as weight in kilograms divided by the square of height in meters.
2MET denotes metabolic equivalent. MET-hours = sum of the average time/week spent in each activity x MET value of each activity.
3Regular aspirin user was defined as consumption of 2 or more 325-mg tablets per week. Non-regular user was defined otherwise.
4Intakes were estimated with food-frequency questionnaire in 1990 except for iron supplement use from the 1992 questionnaire.
5Nutrient values were energy-adjusted intake.
6The serum ferritin levels were measured in a random sample of 305 men in HPFS.
doi:10.1371/journal.pone.0039319.t001
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interaction $0.15; data not shown). We conducted sensitivity
analyses to further adjustment for chronic disease such as
cardiovascular disease, hypertension, and history of diabetes or
restricted to men without gastrointestinal bleeding and inflamma-
tory conditions such as myocardial infarction, stroke, coronary
artery bypass graft angina or rheumatoid arthritis and results were
essentially unchanged (data not shown). Given that approximately
70–80% of colorectal cancer in developed countries is colon
cancer, [25] we classified 78 colorectal cancer cases with unknown
information on sub-site into the colon cancer. Sensitivity analysis
excluding these cases did not change the results (data not shown).
A total of 224 deaths from colorectal cancer (fatal colorectal
cancer) were identified. The number of lifetime blood donations
was not associated with colorectal cancer mortality. Similar to the
results from analyses of colorectal cancer incidence, age-adjusted
results were essentially the same as the multivariable-adjusted
results (Table 3).
Discussion
Frequent blood donation, a marker of body iron stores, was not
associated with colorectal cancer risk in this prospective study of
35,121 middle-aged to elderly U.S. male health professionals. Our
findings do not support an important association between body
iron stores, reflected by serum ferritin levels, and colorectal cancer
incidence and mortality in men.
Limitations of our studies warrant consideration. We only
queried the information on the number of blood donations once
and when the donations were made is uncertain. Thus, the
misclassification of the number of blood donations is possible and
how the timing of blood donations may have influenced the
current results is uncertain. In addition, our study population is
men only and we lack data on blood donation in premenopausal
women, who tend to have much lower ferritin levels due to
menstrual bleeding and pregnancy. [24,26,27] Moreover, al-
though our study is large overall, we had limited numbers for
analysis of mortality as well as analysis of incidence among certain
sub-sites. Further, the healthy donor effect might explain the lack
of an association but regular blood donors in these male
professionals were generally comparable with non-donors with
respect to characteristics shown in Table 1.
Strengths of this study include its large size, prospective design,
long follow-up time and high follow-up rate. Because of the
observed approximate 2-fold difference in serum ferritin levels by
frequency of blood donations, the iron-colorectal cancer hypoth-
esis can be reasonably tested using blood donation as a surrogate.
Table 2. The relative risks of colorectal cancer and sub-sites according to lifetime number of blood donations in the Health
Professionals Follow-up Study (1992–2008).
Number of blood donations
Pf o r
trend
0 1–5 6–9 10–19 20–29 $30
Colorectal cancer No of Cases (n=684) 257 220 68 69 33 37
Model 1
1 1.0 (reference) 0.90 (0.75,1.08) 0.84 (0.64,1.10) 0.95 (0.72,1.24) 0.93 (0.64,1.35) 0.97 (0.69,1.38) .0.99
Model 2
2 1.0 (reference) 0.92 (0.76,1.10) 0.85 (0.65,1.11) 0.96 (0.73,1.27) 0.93 (0.64,1.35) 0.97 (0.69,1.38) 0.99
Model 3
3 1.0 (reference) 0.92 (0.77,1.11) 0.85 (0.64,1.11) 0.96 (0.73,1.26) 0.91 (0.63,1.32) 0.97 (0.68,1.38) 0.92
Colon cancer No of Cases (n=529) 208 166 50 47 27 31
Model 1
1 1.0 (reference) 0.85 (0.69,1.05) 0.76 (0.56,1.05) 0.81 (0.59,1.12) 0.94 (0.63,1.42) 1.02 (0.69,1.49) 0.82
Model 2
2 1.0 (reference) 0.86 (0.70,1.06) 0.77 (0.56,1.05) 0.81 (0.59,1.12) 0.94 (0.62,1.42) 1.00 (0.68,1.47) 0.89
Model 3
3 1.0 (reference) 0.87 (0.70,1.07) 0.77 (0.56,1.06) 0.81 (0.58,1.12) 0.92 (0.61,1.39) 1.00 (0.68,1.47) 0.94
Rectal cancer No of Cases (n=155) 49 54 18 22 6 6
Model 1
1 1.0 (reference) 1.12 (0.75,1.65) 1.14 (0.66,1.97) 1.52 (0.91,2.54) 0.90 (0.38,2.14) 0.80 (0.34,1.88) 0.69
Model 2
2 1.0 (reference) 1.15 (0.77,1.70) 1.18 (0.68,2.05) 1.61 (0.96,2.70) 0.87 (0.36,2.08) 0.86 (0.36,2.02) 0.79
Model 3
3 1.0 (reference) 1.14 (0.77,1.71) 1.18 (0.68,2.06) 1.60 (0.95,2.71) 0.85 (0.35,2.05) 0.87 (0.36,2.05) 0.79
Proximal colon
cancer
No of Cases (n=243) 89 84 21 21 12 16
Model 1
1 1.0 (reference) 1.04 (0.77,1.41) 0.78 (0.48,1.26) 0.87 (0.54,1.41) 1.00 (0.54,1.84) 1.24 (0.72,2.14) 0.55
Model 2
2 1.0 (reference) 1.04 (0.77,1.41) 0.79 (0.49,1.28) 0.89 (0.55,1.44) 1.02 (0.55,1.88) 1.20 (0.70,2.07) 0.62
Model 3
3 1.0 (reference) 1.05 (0.78,1.43) 0.81 (0.50,1.31) 0.88 (0.54,1.44) 1.00 (0.54,1.86) 1.19 (0.68,2.05) 0.68
Distal Colon
cancer
No of Cases (n=189) 72 57 23 16 10 11
Model 1
1 1.0 (reference) 0.83 (0.58,1.17) 0.99 (0.61,1.60) 0.74 (0.43,1.28) 1.08 (0.55,2.10) 0.99 (0.52,1.89) 0.87
Model 2
2 1.0 (reference) 0.84 (0.59,1.19) 1.00 (0.62,1.62) 0.74 (0.43,1.30) 1.09 (0.55,2.13) 0.99 (0.52,1.89) 0.88
Model 3
3 1.0 (reference) 0.84 (0.59,1.20) 0.99 (0.61,1.61) 0.73 (0.42,1.28) 1.07 (0.54,2.11) 0.97 (0.51,1.86) 0.94
1adjusted for age (in months).
2adjusted for age (in months), smoking before age 30 (0, 1–4, 5–10, or .10 pack-years), history of colorectal cancer in a parent or sibling (yes, no), history of
colonoscopy or sigmoidoscopy (yes, no), regular aspirin use (yes, no), body mass index (,25, 25–,30, $30 kg/m
2), physical activity (,3, 3–,27, $27 MET-hrs/wk).
3adjusted for age (in months), factors listed in model 2, consumption of processed meat (quintiles), consumption of beef, pork, or lamb as a main dish (quintiles), alcohol
consumption (0–,5, 5–,10, 10–,15, or $15 g/d), multivitamin use (yes, no), energy-adjusted total calcium intake (quintiles), total folate intake (quintiles), and total
vitamin D intake (quintiles).
doi:10.1371/journal.pone.0039319.t002
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practice across categories of blood donation group and the null
results from mortality analysis appear to decrease concerns that
the observed results were influenced by detection bias. Moreover,
although it cannot be totally ruled out, unmeasured confounding
seems unlikely to have totally cancelled or reversed our results
because the age-adjusted and multivariable-adjusted results were
essentially the same.
Iron is vital for human health and iron deficiency can cause
anemia. [2,9] But iron is a pro-oxidant and high iron levels can
form reactive oxygen species and free radicals and cause DNA
damage. [1,2] In addition, tumor cells grow better in an iron-rich
environment [28] suggesting a potential role of iron in neoplastic
cell proliferation. Thus, excessive iron may increase cancer risk.
The hypothesis of depletion of iron reducing colorectal cancer risk
[29] has been examined in many epidemiologic studies of
biochemical markers, dietary intakes, and genetic mutations, but
the results have been conflicting. Human observational studies of
colorectal cancer risk in relation to endogenous body iron stores,
[3,5,9,12] measured by serum iron, transferrin saturation and total
iron binding capacity yielded mixed results. Some studies found
suggestions of an inverse association, [3] but others reported no
relation [5,12] or even the possibility of an increased risk. [9]
Although not totally understood, one single time measurement of
iron status such as serum iron and transferrin saturation may not
reliably correlate with the body iron stores, [2] which may partly
explain the inconsistent results. In addition, results from studies of
exogenous intakes of iron [4,6,7,10,12,13,30] including dietary
iron and heme iron, the more bioavailable form of iron compared
with other forms of iron, have also been inconclusive. A recent
meta-analysis of five studies of heme iron reported a modest
positive association between heme iron intake and colon cancer
risk (highest vs. lowest quintile, RR=1.18, 95%CI: 1.06, 1.32; P
value for heterogeneity =0.18). [31] Heme iron, mainly found in
animal foods, has been shown to have cytotoxic effects in rats [32]
and to increase formation of endogenous intestinal N-nitroso
compounds, [33] established human carcinogens. Given that iron
absorption is generally tightly regulated, [2] suggestive positive
associations with heme iron indicated that luminal exposure to the
unabsorbed iron might play a role in colorectal carcinogenesis. If
elevated body iron stores is a risk factor for colorectal cancer,
individuals with hereditary hemochromatosis (HFE) characterized
by iron overload would have a higher risk. However, positive
associations with mutations in HFE, the gene for hereditary
hemochromatosis, were reported in some studies, [34,35] but not
in others. [36,37,38] In addition, investigations of iron related
biomarkers, intake, and gene mutations in relation to risk of
adenomas, [12,35,36] precursor lesions of colorectal cancer also
yielded mixed results. Collectively, the inconsistency appeared not
to be totally explained by differences in study design, iron related
variables examined, or adjustment for confounding factors and the
effect of endogenous or extraneous iron on colorectal cancer risk
remains uncertain. Of note, based on an average of 4.5 years of
follow-up, risk of colorectal cancer was lower in an iron reduction
group (4 vs. 9 cases in control group) in a recent clinical trial of
phlebotomy for reduction of iron stores among older most male
patients with advanced peripheral arterial disease. [39] The trial
was not originally designed to compare cancer risk and the lower
range of the iron levels among those patients who did not develop
cancer cannot be generalized to general population to reduce
cancer incidence.
Given that blood donation is good marker of serum ferritin as
shown here and in previous studies, [14,22] the iron-colorectal
cancer hypothesis can also be tested by examining risk of
colorectal cancer between frequent blood donors versus non-
regular donors. Low risk of cancer incidence and mortality has
been reported among blood donors [16,17,18] but the results may
reflect the healthy lifestyle and good health condition of the donor
groups. [19] Recently, one study used a nested case-control study
design and investigated the possible effects of iron loss that resulted
from blood donation in a cohort of Swedish and Danish blood
donors. [19] They observed a suggestive trend (P trend ,0.001) of
decreasing risk for cancers of liver, lung, colon, stomach, and
esophagus combined among men with a latency of 3–7 years
comparing the lowest to the highest estimated iron loss
(OR=0.70, 95%CI:0.58,0.84). [19] However, as recognized by
the authors, how the observed results were affected by unmeasured
confounding factors such as smoking, alcohol consumption, body
mass index, physical activity, and occupation exposures remains
unclear. [19] They concluded that repeated blood donation was
not associated with increased or decreased risk of cancer overall.
[19] In addition, no separate estimates were reported for colon
cancer in that study due to small numbers, which does not allow
direct comparison with our results. Nonetheless, the null
associations observed in our study are generally consistent with
their conclusion. In addition, in the same cohort examined here,
intakes of iron and heme iron were not significantly associated
with colorectal cancer risk. [13].
In summary, frequent blood donation was not significantly
associated with colorectal cancer incidence and mortality among
Table 3. The relative risks of fatal colorectal cancer according to lifetime number of blood donations in the Health Professionals
Follow-up Study (1992–2008).
Number of blood donations P for trend
0 1–5 6–9 10–19 $20
Colorectal cancer No of deaths 85 76 21 18 24
Model 1
1 1.0 (reference) 1.00 (0.73,1.36) 0.88 (0.54,1.44) 0.80 (0.50,1.34) 1.12 (0.71,1.78) 0.97
Model 2
2 1.0 (reference) 0.99 (0.72,1.35) 0.93 (0.57,1.51) 0.84 (0.50,1.41) 1.14 (0.71,1.81) 0.84
Model 3
3 1.0 (reference) 0.99 (0.72,1.36) 0.93 (0.57,1.51) 0.85 (0.50,1.42) 1.14 (0.72,1.83) 0.82
1adjusted for age (in months).
2adjusted for age (in months), smoking before age 30 (0, 1–4, 5–10, or .10 pack-years), history of colorectal cancer in a parent or sibling (yes, no), history of
colonoscopy or sigmoidoscopy (yes, no), regular aspirin use (yes, no), body mass index (,25, 25–,30, $30 kg/m
2), physical activity (,3, 3–,27, $27 MET-hrs/wk).
3adjusted for age (in months), factors listed in model 2, consumption of processed meat (quintiles), consumption of beef, pork, or lamb as a main dish (quintiles), alcohol
consumption (0–,5, 5–,10, 10–,15, or $15 g/d), multivitamin use (yes, no), energy-adjusted total calcium intake (quintiles), total folate intake (quintiles), and total
vitamin D intake (quintiles).
doi:10.1371/journal.pone.0039319.t003
Blood Donation and Colorectal Cancer
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iron stores may not play an important role in colorectal
carcinogenesis.
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